Johnson & Johnson Net Profit Margin 1986-2025 | JNJ

Current and historical net profit margin for Johnson & Johnson (JNJ) from 1986 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue. Johnson & Johnson net profit margin for the three months ending June 30, 2025 was .
Johnson & Johnson Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2025-06-30 $90.63B $22.66B 25.00%
2025-03-31 $89.33B $21.81B 24.41%
2024-12-31 $88.82B $14.07B 15.84%
2024-09-30 $87.70B $14.68B 16.74%
2024-06-30 $86.58B $38.02B 43.91%
2024-03-31 $85.65B $38.48B 44.92%
2023-12-31 $85.16B $35.15B 41.28%
2023-09-30 $76.31B $34.62B 45.37%
2023-06-30 $74.96B $13.05B 17.42%
2023-03-31 $77.46B $12.72B 16.43%
2022-12-31 $79.99B $17.94B 22.43%
2022-09-30 $77.21B $19.16B 24.81%
2022-06-30 $80.55B $18.37B 22.80%
2022-03-31 $79.85B $19.83B 24.84%
2021-12-31 $78.74B $20.88B 26.52%
2021-09-30 $91.45B $17.88B 19.55%
2021-06-30 $89.19B $17.77B 19.92%
2021-03-31 $84.21B $15.12B 17.95%
2020-12-31 $82.58B $14.71B 17.82%
2020-09-30 $80.86B $16.99B 21.01%
2020-06-30 $80.50B $15.19B 18.86%
2020-03-31 $82.73B $17.17B 20.75%
2019-12-31 $82.06B $15.12B 18.42%
2019-09-30 $81.71B $14.15B 17.32%
2019-06-30 $81.33B $16.33B 20.08%
2019-03-31 $81.59B $14.68B 17.99%
2018-12-31 $81.58B $15.30B 18.75%
2018-09-30 $81.38B $1.54B 1.89%
2018-06-30 $80.68B $1.37B 1.70%
2018-03-31 $78.69B $1.25B 1.58%
2017-12-31 $76.45B $1.30B 1.70%
2017-09-30 $74.36B $15.83B 21.28%
2017-06-30 $72.53B $16.34B 22.52%
2017-03-31 $72.17B $16.51B 22.87%
2016-12-31 $71.89B $16.54B 23.01%
2016-09-30 $71.60B $15.94B 22.27%
2016-06-30 $70.88B $15.03B 21.20%
2016-03-31 $70.18B $15.55B 22.15%
2015-12-31 $70.07B $15.41B 21.99%
2015-09-30 $70.52B $14.72B 20.87%
2015-06-30 $71.88B $16.11B 22.41%
2015-03-31 $73.59B $15.92B 21.63%
2014-12-31 $74.33B $16.32B 21.96%
2014-09-30 $74.43B $17.32B 23.27%
2014-06-30 $73.54B $15.55B 21.15%
2014-03-31 $71.92B $15.06B 20.94%
2013-12-31 $71.31B $13.83B 19.40%
2013-09-30 $70.52B $12.88B 18.26%
2013-06-30 $69.99B $12.87B 18.38%
2013-03-31 $68.59B $10.44B 15.22%
2012-12-31 $67.22B $10.85B 16.14%
2012-09-30 $65.92B $8.50B 12.90%
2012-06-30 $64.87B $8.74B 13.47%
2012-03-31 $65.00B $10.11B 15.55%
2011-12-31 $65.03B $9.67B 14.87%
2011-09-30 $64.42B $11.40B 17.69%
2011-06-30 $63.40B $11.61B 18.32%
2011-03-31 $62.13B $12.28B 19.77%
2010-12-31 $61.59B $13.33B 21.65%
2010-09-30 $62.49B $13.60B 21.76%
2010-06-30 $62.59B $13.53B 21.61%
2010-03-31 $62.50B $13.29B 21.26%
2009-12-31 $61.90B $12.27B 19.82%
2009-09-30 $60.53B $12.77B 21.10%
2009-06-30 $61.37B $12.74B 20.76%
2009-03-31 $62.58B $12.86B 20.55%
2008-12-31 $63.75B $12.95B 20.31%
2008-09-30 $64.52B $12.61B 19.54%
2008-06-30 $63.57B $11.85B 18.64%
2008-03-31 $62.25B $11.60B 18.64%
2007-12-31 $61.10B $10.58B 17.31%
2007-09-30 $58.82B $10.37B 17.63%
2007-06-30 $57.14B $10.58B 18.52%
2007-03-31 $55.37B $10.32B 18.64%
2006-12-31 $53.32B $11.05B 20.73%
2006-09-30 $52.25B $10.98B 21.01%
2006-06-30 $51.28B $10.76B 20.98%
2006-03-31 $50.67B $10.53B 20.77%
2005-12-31 $50.51B $10.06B 19.92%
2005-09-30 $50.66B $8.85B 17.48%
2005-06-30 $49.90B $8.66B 17.35%
2005-03-31 $48.62B $8.53B 17.54%
2004-12-31 $47.35B $8.18B 17.28%
2004-09-30 $45.85B $9.14B 19.93%
2004-06-30 $44.75B $8.87B 19.82%
2004-03-31 $43.60B $7.62B 17.48%
2003-12-31 $41.86B $7.20B 17.19%
2003-09-30 $40.01B $6.74B 16.84%
2003-06-30 $38.64B $6.39B 16.54%
2003-03-31 $37.38B $6.83B 18.28%
2002-12-31 $36.30B $6.60B 18.17%
2002-09-30 $35.12B $6.32B 17.99%
2002-06-30 $34.10B $6.12B 17.95%
2002-03-31 $33.21B $5.95B 17.92%
2001-12-31 $32.32B $5.67B 17.54%
2001-09-30 $31.20B $5.45B 17.48%
2001-06-30 $30.58B $5.25B 17.16%
2001-03-31 $30.07B $5.13B 17.06%
2000-12-31 $29.54B $4.89B 16.56%
2000-09-30 $29.30B $4.75B 16.22%
2000-06-30 $28.75B $4.54B 15.80%
2000-03-31 $28.05B $4.34B 15.48%
1999-12-31 $27.47B $4.17B 15.17%
1999-09-30 $27.06B $3.52B 12.99%
1999-06-30 $25.99B $3.37B 12.96%
1999-03-31 $24.89B $3.22B 12.94%
1998-12-31 $24.00B $3.00B 12.52%
1998-09-30 $23.16B $3.53B 15.25%
1998-06-30 $22.93B $3.42B 14.92%
1998-03-31 $22.75B $3.31B 14.56%
1997-12-31 $22.63B $3.30B 14.60%
1997-09-30 $22.50B $3.23B 14.35%
1997-06-30 $22.32B $3.12B 14.00%
1997-03-31 $22.00B $3.01B 13.66%
1996-12-31 $21.62B $2.89B 13.35%
1996-09-30 $20.96B $2.80B 13.34%
1996-06-30 $20.30B $2.67B 13.15%
1996-03-31 $19.68B $2.54B 12.90%
1995-12-31 $18.84B $2.40B 12.75%
1995-09-30 $18.09B $2.32B 12.81%
1995-06-30 $17.39B $2.22B 12.76%
1995-03-31 $16.54B $2.12B 12.79%
1994-12-31 $14.97B $2.01B 13.40%
1994-09-30 $14.41B $1.96B 13.62%
1994-06-30 $13.88B $1.89B 13.63%
1994-03-31 $13.51B $1.83B 13.53%
1993-12-31 $14.14B $1.79B 12.64%
1993-09-30 $14.11B $1.76B 12.47%
1993-06-30 $14.08B $1.72B 12.21%
1993-03-31 $13.96B $1.68B 12.01%
1992-12-31 $13.75B $1.65B 11.99%
1992-09-30 $13.40B $1.62B 12.06%
1992-06-30 $13.04B $1.57B 12.00%
1992-03-31 $12.66B $1.52B 12.00%
1991-12-31 $12.45B $1.46B 11.74%
1991-09-30 $12.00B $1.42B 11.83%
1991-06-30 $11.75B $1.37B 11.66%
1991-03-31 $11.54B $1.32B 11.41%
1990-12-31 $11.23B $1.14B 10.18%
1990-09-30 $11.00B $1.11B 10.12%
1990-06-30 $10.59B $1.07B 10.06%
1990-03-31 $10.15B $1.01B 9.94%
1989-12-31 $9.76B $1.08B 11.09%
1989-09-30 $9.49B $1.06B 11.21%
1989-06-30 $9.23B $1.04B 11.24%
1989-03-31 $9.13B $1.01B 11.08%
1988-12-31 $9.00B $0.97B 10.82%
1988-09-30 $8.73B $0.95B 10.91%
1988-06-30 $8.57B $0.92B 10.77%
1988-03-31 $8.34B $0.88B 10.50%
1987-12-31 $8.01B $0.83B 10.40%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $450.090B $94.943B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12